Phaseline

Companies › Gedeon Richter

Gedeon Richter: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 4, 1 Phase 3; Psychiatry; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cariprazine
Dopamine D3 receptor modulator; Dopamine D2 receptor modulator
DRD3, DRD2Phase 3Schizophrenia; Depression, Bipolar; Bipolar I DisorderDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03817502CariprazinePhase 3SchizophreniaPsychiatryDec 2026
NCT05913947CariprazinePhase 4Depression, BipolarPsychiatrySep 2028
NCT06433635CariprazinePhase 4Bipolar I DisorderPsychiatryFeb 2030

Targets

DRD3 (1) DRD2 (1)

Companies with the same targets

LB Pharmaceuticals Serina Therapeutics Boryung Pharmaceutical Anxo Pharmaceutical Mapi Pharma AbbVie MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals Navamedic NeuroDerm Prilenia

Companies built like this

LB Pharmaceuticals Reviva Pharmaceuticals Cybin IRL Beijing Union Pharmaceutical Factory Newron Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.